Abonnement à la biblothèque: Guest
Portail numérique Bibliothèque numérique eBooks Revues Références et comptes rendus Collections
Critical Reviews™ in Oncogenesis
SJR: 0.631 SNIP: 0.503 CiteScore™: 2.2

ISSN Imprimer: 0893-9675
ISSN En ligne: 2162-6448

Critical Reviews™ in Oncogenesis

DOI: 10.1615/CritRevOncog.2017021084
pages 399-411

IAPs: Mediators of Oncogenesis and Targets for Anticancer Therapy

Sarra Bouaouiche
École Pratique des Hautes Études (EPHE), PSL Research University, Paris, France; Laboratoire d'Immunologie et Immunothérapie des Cancers (LIIC), Université de Bourgogne Franche-Comté, Dijon, France
Laurence Dubrez
Université de Bourgogne Franche-Comté, LNC UMR1231, Dijon, France; Institut National de la Santé et de la Recherche Médicale (Inserm), LNC UMR1231, Dijon, France
Ali Bettaieb
École Pratique des Hautes Études (EPHE), PSL Research University, Paris, France; Laboratoire d'Immunologie et Immunothérapie des Cancers (LIIC), Université de Bourgogne Franche-Comté, Dijon, France
Stéphanie Plenchette
École Pratique des Hautes Études (EPHE), PSL Research University, Paris, France; Laboratoire d'Immunologie et Immunothérapie des Cancers (LIIC), Université de Bourgogne Franche-Comté, Dijon, France

RÉSUMÉ

The inhibitor of apoptosis (IAP) family members are potent regulators of cell homeostasis able to regulate several fundamental cellular processes that include cell death, cell proliferation, cell differentiation, and inflammation. Regarding this broad spectrum of activity, it is now becoming clear that some members of the family possess oncogenic properties. Analysis of genomic database from tumor sequencing studies has revealed a number of genetic alterations affecting some IAP genes and resulting in gain or loss of function. In this review, we discuss the importance of IAP alterations in cell transformation and their link with key oncogenic pathways, focusing on nuclear factor-kappa B (NF-κB)–activating signaling pathways. Then we highlight the therapeutic potential of IAP antagonists and nitric oxide (NO) donors as inhibitors of NF-κB in anticancer therapy.


Articles with similar content:

A New Linkage between the Tumor Suppressor RKIP and Autophagy: Targeted Therapeutics
Critical Reviews™ in Oncogenesis, Vol.23, 2018, issue 5-6
Yuhao Wang, Benjamin Bonavida
YY1 Is an Inducer of Cancer Metastasis
Critical Reviews™ in Oncogenesis, Vol.22, 2017, issue 1-2
Guangchao Sui, Dangdang Li, Wenmeng Wang
The Role of Transcription Factor YY1 in the Biology of Cancer
Critical Reviews™ in Oncogenesis, Vol.22, 2017, issue 1-2
Neeraj Agarwal, Dan Theodorescu
The Novel Role of Yin Yang 1 in the Regulation of Epithelial to Mesenchymal Transition in Cancer Via the Dysregulated NF-κB/Snail/YY1/RKIP/PTEN Circuitry
Critical Reviews™ in Oncogenesis, Vol.16, 2011, issue 3-4
Stavroula Baritaki, Benjamin Bonavida
The Role of the Androgen Receptor in Prostate Cancer
Critical Reviews™ in Eukaryotic Gene Expression, Vol.12, 2002, issue 3
Haojie Huang, Donald J. Tindall